Novaliq named Finalist in “Clinical Trial Result of the Year” category of the Clinical & Research Excellence Awards CARE 2019

HEIDELBERG, Germany--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/CyclASol?src=hash" target="_blank"gt;#CyclASollt;/agt;--Novaliq, the pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on the water-free EyeSol® technology, has been named a finalist in “Clinical Trial Result of the Year” category of the CARE Awards, which recognizes outstanding work across the global clinical research enterprise. In 2018, Novaliq conducted the SEECASE trial which enrolled 336 patients at ten clinical sites in the United States

Full Story →